insights_auto
Why is NTLA down ၃.၇၅%?
Dive Deeperchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
၁၂.၅၈ US$
arrow_downward
-၃.၇၅%(-၀.၄၉) 1D
၁၂.၆၀ US$
arrow_upward
+၀.၁၆% (+၀.၀၂၀)todayPre-market
Closed: အောက် ၁၂, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NTLA...
Open
၁၃.၀၈ US$
High
၁၃.၂၃ US$
Low
၁၂.၅၆ US$
Mkt. cap
၁၇၆.၂၈ ဋေ
Avg. vol.
၄.၉၄ သန်း
Volume
၂.၄၂ ထောင်
52-wk high
၂၈.၂၄ US$
52-wk low
၇.၉၅ US$
EPS
-၃.၃၆ US$
Beta
၁.၈၀
Shares outstanding
၁၄.၀၁ ကုဋေ
No. of employees
၃၇၇
Open
၁၃.၀၈ US$
High
၁၃.၂၃ US$
Low
၁၂.၅၆ US$
Mkt. cap
၁၇၆.၂၈ ဋေ
Avg. vol.
၄.၉၄ သန်း
Volume
၂.၄၂ ထောင်
52-wk high
၂၈.၂၄ US$
52-wk low
၇.၉၅ US$
EPS
-၃.၃၆ US$
Beta
၁.၈၀
Shares outstanding
၁၄.၀၁ ကုဋေ
No. of employees
၃၇၇
News stories
From web sources and news partners
24/7 Wall St.
·
ပြီးခဲ့သည့် ၁၉ မိနစ်
Buffett Says a Know-Nothing Investor Can Beat the Pros. $250 a Month in the S&P 500 Could Turn Into $508,000
The Motley Fool
·
ပြီးခဲ့သည့် ၂၅ မိနစ်
If I Could Invest $1,000 in Just 1 Dividend Stock for the Next 5 Years, I'd Pick This Clear Standout Over the Vanguard S&P 500 ETF (VOO)
WSJ
·
ပြီးခဲ့သည့် ၂ နာရီ
Nasdaq Futures Fall as Global AI Selloff Intensifies
CoinDesk
·
ပြီးခဲ့သည့် ၇ နာရီ
Bitcoin rebounds above $83,000 as it decouples from tumbling Korean stocks and Nasdaq futures
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees၃၇၇
Founded၂၀၁၄
Headquartersကင်းဘရစ်ချ်, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteintelliatx.com